MacroGenics, Inc.
Pharmaceutical Compositions of a HER2/neu Antibody and Use of the Same
Last updated:
Abstract:
The present invention is directed in part to pharmaceutical compositions for storage and administration comprising a) a HER2/neu antibody ("margetuximab"), b) buffering agents, and c) stabilizers, wherein said margetuximab is stable. The invention in part provides, containers and kits comprising such pharmaceutical compositions. The invention is directed in part to the use of such pharmaceutical compositions, containers, and kits containing margetuximab in the treatment of HER2/neu-positive cancer (i.e., a cancer that expresses HER2), including breast cancer or gastric cancer or GEJ cancer.
Status:
Application
Type:
Utility
Filling date:
3 Dec 2021
Issue date:
9 Jun 2022